Lung Carcinoids—Time to Change Practices
Current Oncology · 2026
DOI: 10.3390/curroncol33010050 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Current Oncology, 2026. Verfasst von Ana Rodrigues und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Portuguese Oncology Institute of Porto, 4200-072 Porto, Portugal. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoid Tumor. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Lung carcinoids—typical and atypical—are rare neuroendocrine tumors (NETs) representing 1–2% of lung cancers. Despite clinicopathological differences, their clinical management often mirrors lung cancer protocols rather than NET-specific recommendations.
Objectives
Portray a 12-year real-world experience with lung carcinoids at a Comprehensive Cancer Center, identifying gaps in diagnostic work-up, treatment decision-making, and follow-up.
Methods
Retrospective observational cohort study of adult patients with histologically confirmed lung carcinoids diagnosed at IPO Porto between January 2013 and December 2024. Demographic, clinical, imaging, and treatment data were collected from electronic patient records. Analyses were descriptive.
Results
Among 179 identified cases, 129 met eligibility criteria. Median age was 62 years (range 18–84); 53.6% were women and 53.5% were non-smokers; 84.5% had ECOG-PS 0–1. The most frequent presentation was respiratory symptoms (34.1%), followed by incidental findings (43.4%, of which ~20% were during staging or surveillance of other cancers). Typical carcinoids accounted for 49.6% and atypical for 43.4%. FDG-PET/CT was requested in 70.9% of cases, including many with typical carcinoid, and SSTR-PET/CT in 64.6% (dual PET in 38.8%). Most patients (65.1%) presented with stage I disease; 17.1% were stage IV. Mean time-to-first treatment was 83 days (range 1–259). Surgery was the first treatment option for 78.3% of patients.
Conclusions
This real-world series highlights heterogeneity in diagnostic pathways, excessive FDG-PET use in typical carcinoids, and non-standardized follow-up. Dedicated multidisciplinary lung-NET boards and national reference centers are needed to homogenize and streamline patient management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, Portuguese Oncology Institute of Porto, 4200-072 Porto, Portugal.
- Thoracic and Mediastinal Tumors Clinic, Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), 4200-162 Porto, Portugal.
- Department of Pathology, Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), 4200-162 Porto, Portugal.
- Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP) IPOP/CI-IPOP@RISE (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruc…
- Department of Nuclear Medicine, Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), 4200-162 Porto, Portugal.
- Department of Pathology and Molecular Immunology, ICBAS-School of Medicine & Biomedical Sciences, University of Porto, 4050-313 Porto, Portugal.
ORCID-Profile: Ana Rodrigues, Nuno Coimbra, Carmen Jerónimo, Rui Henrique
Zitieren
APA
Rodrigues, A., Coimbra, N., Sampaio, I. L., Azevedo, I., Soares, M., Jerónimo, C., & Henrique, R. (2026). Lung Carcinoids—Time to Change Practices. Current Oncology. https://doi.org/10.3390/curroncol33010050
Vancouver
Rodrigues A, Coimbra N, Sampaio IL, Azevedo I, Soares M, Jerónimo C, et al. Lung Carcinoids—Time to Change Practices. Current Oncology. 2026. doi:10.3390/curroncol33010050
BibTeX
@article{Rodrigues2026,
author = {Rodrigues, Ana and Coimbra, Nuno and Sampaio, Inês Lucena and Azevedo, Isabel and Soares, Marta and Jerónimo, Carmen and Henrique, Rui},
title = {Lung Carcinoids—Time to Change Practices},
journal = {Current Oncology},
year = {2026},
doi = {10.3390/curroncol33010050}
}
EUVIMED